Speech Abstract:
Convergence of Life Sciences and Healthcare
The trajectory of both life sciences and healthcare will be traced, showing how each are converging on a common goal of predictive, preventive, personalized and participatory healthcare and the necessary steps to achieve this goal. The speaker will explain how insight gained from new data sources—including EHR, outpatient data, longitudinal data, research, claims databases, and outside partners—and the common analytic foundation of both healthcare and life science is leading toward improvements in public health.
In order to achieve a networked healthcare and life science industry model, however, necessary transformation! s to the traditional clinical development paradigm must take place. Sponsors will need to embrace a network of partners from hospitals and doctors, to CROs, academia, technology providers and manufacturing. The presenter will describe some of the practical steps that still need to be accomplished, such as the need for transparent data flows across health care and life sciences; defining common terminologies; correlating standards and data sources; establishing best practices; and, most importantly, the increasing focus of health care on implementing an EHR-based infrastructure.
Bio Sketch:
Kostas Kidos is VP of Product Strategy, Pharmacovigilance & Risk Management at Oracle. His role is to work with senior thought leaders and standards bodies in the pharmacovigilance and risk management domain, in order to ensure that Oracle continues to develop technologies that support relevant business needs in a manner that is well integrated with the overall R&D development process. Prior to Oracle, Mr. Kidos was with Merck & Co. for 6 years as a member of the IT senior leadership team responsible for a diverse organization setting and executing the overall strategy on Healthcare IT, Pharmacovigilance, Risk Management, Regulatory, Labeling, Biostatistics, Epidemiology, Clinical content management, Collaboration portals, Licensing, competitive and Regulatory intelligence and various other areas of Drug Development. Before that he was with Bristol-Myers Squibb for over 15 years as the Executive Director of Pharmacovigilance Operations supporting areas such as Adverse Event systems, terminologies, case intake, regulatory submissions, PSURs, risk management and signaling support, co-marketing agreements, product complaints, and training. In parallel to these positions, for 15+ years he has been leading (and with agreement by PhRMA continues to lead) the PhRMA delegations at ICH and ISO TC215 for various safety-related topics, has served as the rapporteur/co-rapporteur for two of those topics (E2B and M5), and co-chaired with FDA a subcommittee on the electronic exchange of safety information.
|
